Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs)
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …

Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to
rapid viral rebound. Here we report the results of a phase IIa open label clinical trial …

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …

Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …

Monotherapy of HIV-1 infection with single antiretroviral agents is ineffective because error-prone
HIV-1 replication leads to the production of drug-resistant viral variants 1 , 2 . …

HIV-1–infected individuals harbor a latent reservoir of infected CD4 + T cells that is not
eradicated by antiretroviral therapy (ART). This reservoir presents the greatest barrier to an HIV-1 …

Despite suppressive combination antiretroviral therapy (ART), latent HIV-1 proviruses persist
in patients. This latent reservoir is established within 48–72 h after infection, has a long half-…

Combination antiretroviral therapy (ART) is highly effective in controlling human immunodeficiency
virus (HIV)-1 but requires lifelong medication due to the existence of a latent viral …

Type 1 interferons (IFN-I) are potent innate antiviral effectors that constrain HIV-1 transmission.
However, harnessing these cytokines for HIV-1 cure strategies has been hampered by an …

A clinical trial was performed to evaluate 3BNC117, a potent anti–HIV-1 antibody, in infected
individuals during suppressive antiretroviral therapy and subsequent analytical treatment …